Researchers from the University of Illinois have identified a new inhibitor of the androgen receptor (AR), CPIC, that would be effective in the treatment of Castration Resistant Prostate Cancer (CRPC). CPIC targets a novel site on the full-length and truncated forms of the AR, present in the CRPC. Initial in vivo data has demonstrated that this new class of compounds is capable of inhibiting growth of prostate cancer cells. Furthermore, CPIC has shown to be 40x more potent against the truncated AR compared to current small molecules against the truncated AR.
Dr. Smith has developed a new class of water-stable nanoplatelets encapsulated in lipoproteins. Nanoplatelets are bright single-molecule emitters, comparable to quantum dots, but with substantially narrower bandwidths. The nanoparticles retain their fluorescence after internalization in cells and thus are suitable for live-cell single-molecule imaging.
This invention is a novel approach to performing DNA sequencing-by-synthesis methodology that is anticipated to make DNA sequencing routine, highly accurate and affordable.
The approach is a silicon-based field effect nanoscale sensor array using a sequence-by-synthesis methodology. PCR is performed locally in each pixel through the use of recently developed methods for heating fluid using a silicon field effect sensor, and then the amplified molecules in the pixel are detected in a label-free electrical manner where the added charge during the synthesis process is detected using the same thin-film SOI transistor.
Cost is significantly reduced since the nucleotides do not need a fluorescent label, there is no need for gel electrophoresis, and the entire machinery of optical signal processing is unnecessary. In addition, since the silicon field effect sensors when used in a nanoscale dimension can be very sensitive and detect the charge from just a few molecules, it is quite feasible that the PCR amplification can be utilized with very few cycles. Reduction of PCR cycling would reduce the usage of costly reagents. The information retrieval can be scaled and the information obtained per unit time is maximized.
Dr. Morrissey from the University of IL has developed a novel assay for quantifying polyP levels in patient plasma. This assay allows for polyP quantitation to be performed quickly and in a clinical setting without purification of polyP from plasma. It uses widely available coagulometer. Accurate quantification of circulating polyP levels in a patient's blood will give insight into potential risk of thrombotic and inflammatory diseases. In addition, polyP levels may be significant in conditions such as cancer, sepsis, and trauma-induced coagulopathy.
Dr. Princess Imoukhuede from University of Illinois has developed a new quantitative receptor measurement approach for examining glioblastomas (GBM) heterogeneity. This approach is a paradigm shift in single-cell technologies: from gene-centric to proteomics. It provides never-before-seen insight into GBM heterogeneity that will ultimately enable more effective cancer treatment. It is a sensitive, quantitative approach that enables high-throughput measurements.
Researchers from the University of Illinois Urbana-Champaign have developed a non-invasive method for the early detection of human papillomavirus (HPV)-positive and -negative head and neck cancer using saliva samples. This method has potential research and clinical applications including diagnosis of HPV-positive and -negative head-and-neck cancer. The approach detects several genes characteristic of each type of cancer HNSCC that are commonly detected in head-and-neck cancer.
Applications: Diagnosis of HPV-positive and -negative head-and-neck cancer; research applications
Non-invasive as it only requires saliva from patient
Saliva-based screening is quick (i.e., hours) and easy as it uses common laboratory equipment
Head-and-neck screening can be completed more than the recommendation of once a year because it is low in cost, fast, and non-invasive.